Vincerx Pharma

55 articles about Vincerx Pharma

• Vincerx Pharma Presents Positive Preliminary Phase 1 Data for VIP236 and Updates on Pipeline Progress at the American Association for Cancer Research (AACR) Annual Meeting 2024 

  4/8/2024

  Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today presented positive preliminary Phase 1 data for VIP236 and updates on pipeline progress at the American Association for Cancer Research (AACR) Annual Meeting 2024.

• Vincerx to Host Virtual Investor Event Reviewing Preliminary Phase 1 VIP236 Data Presented at the American Association for Cancer Research (AACR) Annual Meeting 2024

  4/1/2024

  Vincerx Pharma, Inc. will host a virtual investor event reviewing preliminary clinical data from its Phase 1 dose-escalation study of VIP236 and provide an update on pipeline progress on Monday, April 8, 2024, at 2 PM PT.

• Vincerx Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Update

  3/29/2024

  Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a corporate update.

• Vincerx to Present Three Posters at the American Association for Cancer Research (AACR) Annual Meeting 2024

  3/5/2024

  Vincerx Pharma, Inc. announced it will present three posters at the American Association for Cancer Research Annual Meeting 2024, taking place in San Diego, CA, from April 5 – 10, 2024.

• Vincerx Pharma Announces Compelling Clinical Efficacy of Enitociclib in Combination with Venetoclax and Prednisone in Lymphoma

  1/7/2024

  Vincerx Pharma, Inc. announced promising clinical results from a Phase 1 NIH-sponsored study of enitociclib in combination with venetoclax and prednisone for the treatment of relapsed/refractory lymphoma.

• Vincerx Pharma Presents Preclinical VIP943 and VIP924 Posters at ASH 2023

  12/10/2023

  Vincerx Pharma, Inc. announced the presentation of two preclinical posters at the 65th Annual Meeting of the American Society for Hematology for VIP943, for leukemias and myelodysplastic syndrome, and VIP924, for B-cell malignancies.

• Vincerx Pharma Reports Third Quarter 2023 Financial Results and Provides Corporate Update

  11/14/2023

  Vincerx Pharma, Inc. (Nasdaq: VINC)(“Vincerx”), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today reported financial results for the third quarter ended September 30, 2023 and provided a corporate update.

• Vincerx Pharma To Present Three Posters at ASH 2023 in December

  11/2/2023

  Vincerx Pharma, Inc. announced that it will present three posters related to VIP943, VIP924, and enitociclib at the 65th American Society for Hematology Meeting, taking place in San Diego California from December 9 to 12, 2023.

• Vincerx Pharma to Participate at the Cantor Fitzgerald Global Healthcare Conference 2023

  9/19/2023

  Vincerx Pharma, Inc. today announced that Vincerx’s CEO Ahmed Hamdy, M.D. and the Management Team will participate in a panel presentation and one-on-one investor meetings at the Cantor Fitzgerald Global Healthcare Conference 2023, to be held in New York, NY, September 26-28, 2023.

• Vincerx Pharma Doses First Patient in the Phase 1 Clinical Trial Evaluating VIP943Phase 1 trial enrolling patients with relapsed/refractory AML, MDS and B-cell ALL

  9/14/2023

  Vincerx Pharma, Inc. today reported that the first patient has been dosed in the Phase 1 trial evaluating VIP943 in patients with relapsed/refractory acute myeloid leukemia (R/R AML), myelodysplastic syndrome (MDS), and B-cell acute lymphoblastic leukemia (B-cell ALL).

• Vincerx Pharma Announces FDA Clearance of IND for VIP943

  8/22/2023

  Vincerx Pharma, Inc. today reported that it has received clearance for its Investigational New Drug (IND) application from the U.S. Food and Drug Administration (FDA) to initiate a Phase 1 clinical trial for VIP943.

• Vincerx Pharma Reports Second Quarter 2023 Financial Results and Provides Corporate Update

  8/7/2023

  Vincerx Pharma, Inc. today reported financial results for the second quarter ended June 30, 2023 and provided a corporate update.

• Vincerx Pharma Reports First Quarter 2023 Financial Results and Provides Corporate Update

  5/11/2023

  Vincerx Pharma, Inc., a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, reported financial results for the first quarter ended March 31, 2023 and provided a corporate update.

• Vincerx Pharma Presents Preclinical Data on VIP924, a First-in-Class Antibody-Drug Conjugate (ADC), at the 2023 American Association for Cancer Research (AACR) Annual Meeting

  4/19/2023

  Vincerx Pharma, Inc. today presented a poster of VIP924 preclinical data at the 2023 American Association for Cancer Research (AACR) Annual Meeting.

• Vincerx Pharma Presents Preclinical Data on VIP236, a First-in-Class Small Molecule Drug Conjugate (SMDC), at the 2023 American Association for Cancer Research (AACR) Annual Meeting

  4/17/2023

  Vincerx Pharma, Inc. presented a poster of preclinical data of VIP236 monotherapy treatment in PDX and metastatic PDX mouse models across several tumor types at the 2023 American Association for Cancer Research Annual Meeting.

• Vincerx Pharma Presents Preclinical Data on Novel Small Molecule Drug Conjugates at the American Association for Cancer Research (AACR) Annual Meeting 2023

  4/17/2023

  Vincerx Pharma, Inc. presented a poster of preclinical data on novel integrin αvβ3-targeted small molecule drug conjugates at the American Association for Cancer Research Annual Meeting.

• Vincerx Pharma Reports Fourth Quarter and Full Year 2022 Financial Results and Provides a Corporate Update

  3/28/2023

  Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today reported financial results for the fourth quarter and full year ended December 31, 2022, and provided a corporate update.

• Vincerx Pharma Announces Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2023

  3/14/2023

  Vincerx Pharma, Inc. (Nasdaq: VINC) today announced four poster presentations at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2023, being held virtually and at the Orange County Convention Center in Orlando, Florida from April 14-19, 2023.

• Vincerx Pharma to Participate at the SVB Securities Global Biopharma Conference

  2/6/2023

  Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today announced that Vincerx’s management team will present the company’s corporate overview and participate in one-on-one investor meetings at the SVB Securities Global Biopharma Conference, to be held virtually from February 14-16, 2023.

• Vincerx Pharma Announces FDA Safe to Proceed Letter for Investigational New Drug (IND) Application for its αVβ3 Small Molecule-Drug Conjugate (SMDC) VIP236

  12/13/2022

  Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has provided a safe to proceed letter and cleared the IND application for VIP236, the Company’s front-runner SMDC for the treatment of advanced solid tumors.